Payment overview · 2025
General Payments
$200.99
11 reported records · 7 companies
Healthcare provider profile · identity verified
Cesar Koa Ang, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PLACERVILLE, CA · NPI 1225010218
Verified facts
What the public records show
CMS Open Payments records show Cesar Koa Ang, MD received $200.99 in general payments during 2025 across 11 reported records.
Amgen Inc. accounted for 39.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $78.43 | 39.0% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $36.62 | 18.2% | 2 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $19.92 | 9.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.47 | 9.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.09 | 8.5% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$16.16 | 8.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.30 | 7.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $200.99 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $78.43 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $36.62 | 2 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $19.92 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.09 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.09 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.09 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $16.16 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
94 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
33 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 554 | 149 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 488 | 106 |
| Gabapentin | Gabapentin | 352 | 76 |
| Amlodipine Besylate | Amlodipine Besylate | 346 | 101 |
| Lisinopril | Lisinopril | 326 | 102 |
| Losartan Potassium | Losartan Potassium | 322 | 83 |
| Levothyroxine Sodium | Levothyroxine Sodium | 309 | 82 |
| Omeprazole | Omeprazole | 268 | 73 |
| Metformin Hcl | Metformin Hcl | 211 | 60 |
| Lorazepam | Lorazepam | 168 | 47 |
| Potassium Chloride | Potassium Chloride | 147 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 146 | 46 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 141 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 140 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 133 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 129 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 127 | 37 |
| Sertraline Hcl | Sertraline Hcl | 127 | 35 |
| Tramadol Hcl | Tramadol Hcl | 126 | 29 |
| Trazodone Hcl | Trazodone Hcl | 118 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 110 | 26 |
| Finasteride | Finasteride | 109 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 104 | 38 |
| Simvastatin | Simvastatin | 104 | 32 |
| Alprazolam | Alprazolam | 102 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 96 | 25 |
| Eliquis | Apixaban | 94 | 22 |
| Furosemide | Furosemide | 93 | 30 |
| Spironolactone | Spironolactone | 84 | 20 |
| Donepezil Hcl | Donepezil Hcl | 82 | 25 |
| Ezetimibe | Ezetimibe | 77 | 21 |
| Allopurinol | Allopurinol | 76 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 76 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 22 |
| Celecoxib | Celecoxib | 74 | 22 |
| Ozempic | Semaglutide | 72 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 68 | 48 |
| Carvedilol | Carvedilol | 65 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 15 |
| Famotidine | Famotidine | 65 | 24 |
| Diazepam | Diazepam | 64 | 12 |
| Methylprednisolone | Methylprednisolone | 62 | 49 |
| Montelukast Sodium | Montelukast Sodium | 60 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 23 |
| Cephalexin | Cephalexin | 57 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 16 |
| Glipizide Er | Glipizide | 53 | 14 |
| Ibandronate Sodium | Ibandronate Sodium | 53 | 15 |
| Azithromycin | Azithromycin | 52 | 43 |
| Pregabalin | Pregabalin | 52 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 13 |
| Clonazepam | Clonazepam | 47 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 47 | 21 |
| Atenolol | Atenolol | 46 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 46 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | 13 |
| Memantine Hcl | Memantine Hcl | 45 | 11 |
| Temazepam | Temazepam | 44 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 43 | 14 |
| Metformin Hcl Er | Metformin Hcl | 43 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 15 |
| Januvia | Sitagliptin Phosphate | 42 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 40 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | suppressed |
| Ibuprofen | Ibuprofen | 36 | 17 |
| Jardiance | Empagliflozin | 36 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | 16 |
| Ramipril | Ramipril | 35 | 11 |
| Lovastatin | Lovastatin | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 27 |
| Paxlovid | Nirmatrelvir/Ritonavir | 33 | 33 |
| Baclofen | Baclofen | 32 | 11 |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Meloxicam | Meloxicam | 32 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 17 |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 30 | 16 |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | 11 |
| Estradiol | Estradiol | 26 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 25 | 25 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 18 |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 11 |
| Colchicine | Colchicine | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Nystatin | Nystatin | 15 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Paroxetine Er | Paroxetine Hcl | 13 | suppressed |
| Prednisone | Prednisone | 13 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $200.99 · 11 records | Amgen Inc. | ABRYSVO, AREXVY, COMIRNATY, Doc Band, EVENITY, FREESTYLE LIBRE 3, INCEPTIV, PREVNAR 20, SHINGRIX, The Cologuard Plus Collection Kit | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error